PT - JOURNAL ARTICLE AU - Bell, Joshua A. AU - Santos Ferreira, Diana L. AU - Fraser, Abigail AU - Soares, Ana Luiza G. AU - Howe, Laura D. AU - Lawlor, Deborah A. AU - Carslake, David AU - Smith, George Davey AU - O’Keeffe, Linda M. TI - Sex differences in cardiometabolic traits at four life stages: cohort study with repeated metabolomics AID - 10.1101/2020.01.15.19015206 DP - 2020 Jan 01 TA - medRxiv PG - 2020.01.15.19015206 4099 - http://medrxiv.org/content/early/2020/01/16/2020.01.15.19015206.short 4100 - http://medrxiv.org/content/early/2020/01/16/2020.01.15.19015206.full AB - Background Males experience higher rates of coronary heart disease (CHD) than females, but the circulating traits underpinning this difference are poorly understood. We examined sex differences in detailed cardiometabolic traits measured at four life stages, spanning childhood to middle adulthood.Methods and Results Data were from the Avon Longitudinal Study of Parents and Children cohort study. 229 traits quantified from targeted metabolomics (nuclear magnetic resonance spectroscopy) including lipoprotein subclass-specific cholesterol and triglycerides, amino acids, glucose, and inflammatory glycoprotein acetyls were measured repeatedly in offspring (Generation 1 (G1)) born in 1991-92 and once in their parents (Generation 0 (G0)). Measurements in G1 were once in childhood (mean age 8y), twice in adolescence (16y and 18y) and once in early adulthood (25y), and in G0 once in middle adulthood (50y). Linear regression models were used to examine differences in standardized traits for males compared with females on each occasion (serial cross-sectional associations). 7,727 G1s (49% male) and 6,500 G0s (29% male) contributed to analyses. At age 8y, total lipids in very-low-density lipoproteins (VLDL) were lower in males than females; levels were higher in males than females at age 16y and were higher still by age 18y and age 50y (in G0) for medium-or-larger subclasses. Larger sex differences at older ages were most pronounced for triglycerides in VLDL – e.g. male levels were 0.19 standard deviation (SD) units (95% CI=0.12, 0.26) higher at age 18y, 0.50 SD (95% CI=0.42, 0.57) higher at age 25y, and 0.62 SD (95% CI=0.55, 0.68) higher at age 50y. Cholesterol in VLDL and low-density lipoproteins (LDL) was generally lower in males, with inconsistent sex differences across ages. Apolipoprotein-B was generally lower in males than females. Branched chain amino acids were consistently higher in males after age 8y with the largest sex difference of all traits at all ages seen for leucine at age 50y (1.53 SD, 95% CI=1.47, 1.58 higher in males compared with females). Males had consistently lower glycoprotein acetyls across ages.Conclusions Our results suggest that males begin to have higher VLDL triglycerides in adolescence, and that this sex difference is larger at older ages. Sex differences in other CHD-related traits, including LDL cholesterol, apolipoprotein-B, and inflammatory glycoproteins, show the opposite pattern with age, with higher levels among females. Higher triglyceride content may therefore be a key factor underpinning the higher age-adjusted rate of CHD among males; causal analyses of this and other traits are needed to understand whether they differentially affect CHD risk among males and females.Competing Interest StatementThe authors have declared no competing interest.Funding StatementWe are extremely grateful to the families who participated in this study, the midwives for their help in recruiting them, and the whole ALSPAC team which includes interviewers, computer and laboratory technicians, clerical workers, research scientists, volunteers, managers, receptionists, and nurses. The UK Medical Research Council, Wellcome (102215/2/13/2), and the University of Bristol provide core support for ALSPAC. A comprehensive list of grants funding is available on the ALSPAC website (http://www.bristol.ac.uk/alspac/external/documents/grant-acknowledgements.pdf); this research (collection of NMR metabolomics data) was specifically funded by the MRC (MC_UU_12013/1) and NIHR (NF-SI-0611-10196). This publication is the work of the authors who are guarantors for its contents. JAB is supported by Cancer Research UK (C18281/A19169) and the Elizabeth Blackwell Institute for Health Research, University of Bristol and the Wellcome Trust Institutional Strategic Support Fund. AF, ALGS and LDH are funded by UK Medical Research Council research fellowships (MR/M009351/1 & MR/M020894/1, respectively). DAL’s contribution to this work is supported by the European Research Council under the European Union's Seventh Framework Programme (FP/2007-2013) / ERC Grant Agreement (Grant number 669545; DevelopObese), the European Union’s Horizon 2020 research and innovation programme under grant agreement No 733206 (LifeCycle), the United States National Institutes of Health (NIH): National Institute of Diabetes and Digestive and Kidney Diseases (R01 DK10324), the British Heart Foundation (AA/18/7/34219) and National Institute of Health Research ((NF-SI-0611-10196); LMOK is supported by a Health Research Board (HRB) of Ireland Emerging Investigator Award (EIA-2019-007) and a UK Medical Research Council Population Health Scientist fellowship (MR/M014509/1); DLSF, DAL, DC and GDS work in a unit funded by the UK Medical Research Council (MC_UU_00011/1,6) and the University of Bristol. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.Author DeclarationsAll relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.YesAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesIndividual-level ALSPAC data are available following an application. This process of managed access is detailed at www.bristol.ac.uk/alspac/researchers/access. Cohort details and data descriptions are publicly available at the same web address.